For the month ended 31 March 2026, Mabpharm Limited (Mabpharm-B) reported no movements in either authorised or issued share capital, according to the company’s filing with Hong Kong Exchanges and Clearing Limited on 2 April 2026.

Authorised Capital • The authorised share balance remained at 50.00 billion ordinary shares with a par value of USD 0.0001 each, equivalent to total authorised capital of USD 5.00 million.

Issued Shares and Treasury Shares • Issued shares stood unchanged at 4.12 billion. • The company held no treasury shares during the period, and there were no cancellations, transfers or new issues.

Share Option Scheme • Outstanding share options under the 10 August 2018 scheme totalled 72.67 million, identical to the previous month. • No options were exercised and no new shares were issued pursuant to the scheme. The same 72.67 million shares remain available for potential issuance.

Public Float • Mabpharm confirmed compliance with the Main Board’s minimum public float requirement of 25 % of total issued shares (excluding any treasury shares).

Other Instruments • The company reported no warrants, convertible securities, Hong Kong depositary receipts, or other arrangements that could affect share capital.

Administrative Details • The return was signed by company secretary Tsang Ho Yin and designated as a “New Submission”.

Overall, Mabpharm-B’s March 2026 monthly return highlights a stable equity structure with no fundraising or dilution events during the period.